From Belgium: 3D-Bioprinted ‘Waffle’ to Fix Broken Bones POSTED ON FEBRUARY 2, 2016
Bone Therapeutics (Belgium) is a cell therapy biotech working on bone fracture repair which has now extended its collaboration with Kasios (France), to develop next generation bone disease therapy with 3D-Bioprinting technology.
The current standard-of-care in the Bones field involves major surgeries and (consequently) long recovery time. Bone Therapeutics is therefore developing a range of regenerative products containing osteoblasts (bone-forming cells), which can be injected with minimal invasiveness.
Preob, Bone Therapeutics’ autologous bone cell product, is currently in pivotal Phase IIb/III clinical studies for two indications: osteonecrosis (for which it has FDA Orphan Drug Designation), non-union fractures, and phase II trials for severe osteoporosis.
Allob on the other hand is an allogeneic “off-the-shelf” cell product made from adult bone marrow donors. It is in phase I/IIa trials for the treatment of delayed-union fractures and lumbar fusion for degenerative disease of the spine.
Bone Therapeutics Establishes US Subsidiary Bone Therapeutics USA Inc. to be headquartered in the heart of the Boston biotechnology cluster, laying the foundations for its US clinical trial programmes
Regenerative therapies for bone diseases - Bone Therapeutics - english version
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.